Search results
Results From The WOW.Com Content Network
Walgreens said the value of its ill-fated VillageMD merger has fallen so much, it was forced to take a massive $6 billion writedown on its balance sheet. In the past few years, CVS has closed ...
In 2023, Mounjaro drove more than $5 billion in sales, and in the first four months of 2024, doctors issued 63,000 Zepbound prescriptions weekly. ... Evidence of food price gouging is hard to find.
Eli Lilly’s diabetes treatment Mounjaro, which is widely used for weight loss, raked in nearly $1 billion in second-quarter sales, or more than $200 million above what Wall Street had expected.
Tirzepatide is an antidiabetic medication used for the treatment of type 2 diabetes [ 9][ 12][ 13][ 14] and for weight loss. [ 10][ 15] Tirzepatide is administered via subcutaneous injections (under the skin). [ 9][ 12] It is sold under the brand names Mounjaro for diabetes treatment, [ 9] and Zepbound for weight loss. [ 10]
If I remember correctly, it was around $575 for four Mounjaro pens at first. (The price kept going up as the medication got more popular and ended up at about $1,000/month.)
The total price of the acquisition was $4.9 billion in cash and 144.3 million common shares with fair value of $10.7 billion. [3] Walgreens had previously purchased 45% of the company for $4.0 billion and 83.4 million common shares in August 2012 with an option to purchase the remaining shares within three years. [4]
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Eli Lilly wasn’t one of them. The 10 stocks that made the cut ...
August 2, 2024 at 6:03 PM. By Bhanvi Satija and Sneha S K. (Reuters) -All doses of Eli Lilly's weight-loss drug Zepbound and diabetes drug Mounjaro are now available, the U.S. Food and Drug ...